Abstract We report a novel complex mutation that consists of a deletion of 12 bp and an insertion of 2 bp (c.8402_8413del12ins2bp) in the exon 18 of the BRCA2 gene. This is a frameshift mutation that causes a disruption of the translational reading frame resulting in a stop codon downstream in the 2729 position of the BRCA2 protein.
Introduction
Breast cancer is the most commonly occurring cancer among women. Many risk factors have been identified, but a family history of breast cancer is one of the main risk factors for developing the disease.
It is currently estimated that about 5-10% of breast cancers are due to an inherited predisposition, and approximately 20-25% of this risk is explained by two high penetrance susceptibility genes: BRCA1 (17q21) (MIM# 113705) [1] and BRCA2 (13q12-13) (MIM# 600185) [2] . Both are tumor suppressor genes implicated mainly in DNA repair. Mutations in BRCA1 or BRCA2 account for a lifetime risk of approximately 40-65% for breast cancer and 11-40% for ovarian cancer [3] Extensive analyses of the BRCA1 and BRCA2 genes have resulted in the identification of a large number of different disease-causing germ-line mutations (listed online at the Breast Cancer Information Core) [4] . Most reported disease-associated alleles of BRCA1 and BRCA2 consist of small insertions or deletions that generate the occurrence of premature stop codons leading to truncation of BRCA1 or BRCA2 proteins. Less commonly, deletion/insertion (delins) complex mutations have also been described in both the genes. Furthermore, a large number of missense, in-frame, and intron variants (especially those affecting splice sites positions) are routinely encountered in clinical and research laboratories, and cannot be readily distinguished as either disease-associated mutations or benign polymorphisms, and they are classified as variants of uncertain significance (BIC database).
We report a novel complex mutation that consists of a deletion of 12 bp and an insertion of 2 bp (c.8402_ 8413del12ins2bp) in the exon 18 of the BRCA2 gene in three women belonging to a Spanish hereditary male/ female breast cancer family.
Patients
The proband was diagnosed of breast cancer at 37 years of age (infiltrating ductal carcinoma, pT2 pN3a, GIII, ER-, PgR-, HER2-), with non-evidence of disease at 7 years of diagnosis. She has two sisters affected, one of them by breast cancer at 34 years (infiltrating ductal carcinoma, pT1c pN1, GIII, ER?, PgR?, HER2-). She is free of disease at 2 years from diagnosis. The other sister was diagnosed of synchronous bilateral breast cancer at 36 years (left breast: infiltrating lobular carcinoma, pT2 pN3a, GII, ER-, PgR?, HER2-, and right breast: infiltrating ductal carcinoma, pT1c pNx, GII, ER-, PgR?, HER2-) and 2 years after surgery, she has been diagnosed of bone metastasis. Their father died at 52 years of metastatic breast cancer diagnosed at 46 years of age, and a paternal aunt was diagnosed with left breast cancer (pT2a pN0, GII, ER-, PgR?) at 28 years and bilateral papillary serous ovarian carcinoma at age of 45. The paternal grandmother presented breast cancer at the age of 70. Figure 1 shows the pedigree of the affected family.
Methods
As part of genetic studies carried out on breast/ovarian Spanish families from the Genetic Counseling Unit in the Institut Oncologic del Vallès, germ-line BRCA1 and BRCA2 mutations were screened in a proband of each family. Individuals underwent genetic counseling and signed an informed consent prior to testing. The molecular analyses were done in the Oncogenetics laboratory at the University Hospital Vall d'Hebron, Barcelona, Spain.
Genomic DNA was extracted from whole blood using the Puregene Genome DNA purification kit (Gentra System, Minneapolis, MN, USA). DNA was amplified by PCR using primers specific for the coding sequence and exon/ intron boundaries. Analysis of the entire coding and flanking sequences was carried out by sequencing using BigDye Terminator V3.1 Cycle Sequencing Kit on a 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Both forward and reverse strands were sequenced. The variant sequence described in our study is named according to the GenBank (BRCA2 NM_000059).
Results
A novel complex mutation was identified in the exon 18 of the BRCA2 gene: a deletion of 12 bp and an insertion of 2 bp (c.8402_8413delGGTATGCTGTTAinsTT) (Fig. 2) in the index case of a hereditary male/female breast cancer family. After identification of the alteration in the proband the analysis was then carried out on DNA samples obtained from two affected sisters. The same change was detected in the DNA of the two relatives. This alteration is not present in the BIC database nor has been documented in any published report to the best of our knowledge.
Furthermore, all mutation carriers analyzed in the family presented the variant c.296-7T[A in intron 2 of BRCA2, that causes an alternative transcription with the skipping of exon 3, that is present in normal population and is not considered as pathogenic [5, 6] .
Discussion
Since the identification of BRCA1 and BRCA2, more than 3600 distinct genetic variants (including deleterious mutations, polymorphisms, and unclassified variants) have been reported for these genes (BIC database) [4] The great majority are small deletions or insertions that originate premature stop codons and lead to truncated proteins or mRNA degradation. A short number of delins frameshift alterations have also been described across the sequence of both genes (18 in BRCA1 and 15 in BRCA2). As part of genetic studies carried out on breast/ovarian Spanish families, we identified a new delins frameshift alteration in BRCA2 (c.8402_8413del12ins2bp) that causes a disruption of the translational reading frame resulting in a premature stop codon in the 2729 position. According to the HGV rules [7] , it can be assumed that this change has occurred as the consequence of one mutational event, although the same alteration could have occurred as two sequence variants in the same allele: a c.8402_8410del9bp in frame deletion, and a frame shift c.8414delA mutation. The in-frame deletion of nine nucleotides would entail the absence of three amino acids (Trp-Thr-Ala) from codon 2725 to 2727 in the corresponding BRCA2 protein. This modification would have an unknown biological significance. The c.8414delA mutation would result in the appearance of the same stop codon in position 2729, with a clear pathogenic role. Up to the date none of these two potential allelic variants (c.8402_8410del9 bp and c.8414delA) have been described and the simplest HGV nomenclature must be opted.
However, many other presumably deleterious alterations have been reported in its vicinity, in exon 18. The BIC database reports 26 different pathogenic mutations and 43 changes with unknown significance, including two in frame deletions (p.K2750del and p.RLTVG2743del). This last mutation was predicted to result in the deletion of five amino acids (positions 2744-2748) in the carboxyterminal region of the protein, and was found to track exclusively in affected members of a breast/ovarian cancer family [8] . The region of BRCA2 harboring the mutation reveals high evolutionary conservation across species. This region corresponds to the 800-residue carboxyl-terminal domain of BRCA2, which is likely to play an important role in the tumor suppressor functions of the gene. It includes a helical domain (mostly a-helices) followed by three structurally homologous domains that contain three oligonucleotide/ oligosaccharide-binding (OB) folds (OB1, OB2, and OB3). The OB2 has a 130-amino acid insertion that adopts a tower-like structure protruding away from the OB fold [9] . The DSS1 protein, that may have a stabilizing function of BRCA2 within the cell, binds BRCA2 in an extended conformation interacting with the helical domain, OB1 and OB2 domains. Bearing in mind that it is the most conserved portion of BRCA2 across different species and contains a high number of missense mutations found in breast cancer families, it seems reasonable to suggest the changes that occur in this region (even in frame or missense alterations) may be associated with a higher probability to an increase of risk of cancer in the carrier families.
The delins rearrangement here described presumably affects important BRCA2 protein functions since it causes the absence of the C-terminal conserved region in the protein, that mediate binding to RAD51 (directly involved in homologous recombination), and some other proteins like DSS1 [10, 11] . Alternatively, the mutation could originate the degradation of the transcripts by the mRNA nonsense mediated decay mechanism. Consequently, the mutation can be classified as clearly pathogenic and associated to a high risk of female and male breast cancer and ovarian cancer in agreement with the phenotype of the studied family.
In this pedigree, the BRCA2 (c.8402_8413del12ins2bp) mutation cosegregates with breast cancer in the three sisters, all of them affected before 40 years. The age at diagnosis of the breast cancer of the father (46 years) is younger that the mean age of onset of male breast cancer reported in mutation positive families (62.1 years) [12] .
It has not been possible to test the father and the paternal aunt (affected by two primary tumors: very early breast cancer at 28 years, and bilateral ovarian cancer diagnosed at 45 years), that probably carry the familiar mutation. The risk of ovarian cancer in BRCA2 carriers is very low at 50 years of age, but increases sharply in the 50-59 years age group, perhaps declining somewhat thereafter [3] . Together, these findings strongly suggest that the BRCA2 c.8402_8413del12ins2bp mutation is of high penetrance.
